Drug Trial Radar · NCT03935217
A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Last checked: Nov 20, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Apr 23, 2019
Primary completion
Mar 2, 2020
Study completion Mar 25, 2020
Sponsor
- Lead sponsor
- Lupin Research IncIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.
Conditions
- Trichomonas Infection
Interventions
SecnidazoleDrug
Oral Granules containing secnidazole
PlaceboDrug
Oral Granules of placebo manufactured to mimic secnidazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiological Cure at the TOC VisitTime frame: Study Day 6-12
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Site 1007
Birmingham, Alabama
Site 1003
North Miami, Florida
Site 1014
Chicago, Illinois
Site 1013
Jackson, Mississippi
Site 1009
Lawrenceville, New Jersey
Site 1008
Chapel Hill, North Carolina
Site 1004
Fayetteville, North Carolina
Site 1011
Charleston, South Carolina
Site 1001
Memphis, Tennessee
Site 1002
Memphis, Tennessee
Site 1006
Virginia Beach, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.